Therapeutic biomarker differences between MSI-H and MSS colorectal cancers | Caris Life Sciences
Home / Research / Publications / Therapeutic biomarker differences between MSI-H and MSS colorectal cancers

Publications

Therapeutic biomarker differences between MSI-H and MSS colorectal cancers

Background

Approximately 15% of colorectal cancers (CRC) display high level of microsatellite instability (MSI-H) due to either hereditary predisposition (Lynch syndrome, LS) or somatic hypermethylation of MLH1. They carry a significantly different prognosis and responses to treatments compared with microsatellite stable (MSS) or low microsatellite instability (MSI-L) CRC. We
investigated therapeutically important biomarkers, which may underlie different treatment options for CRC.

Download Publication
Learn More
Name(Required)